









Markets
/
Stocks
/
nasdaq-pfe
/

Pfizer Inc

PFE



View Detailed Chart

27.220USD

+0.720+2.72%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

154.77BMarket Cap

19.91P/E TTM



Pfizer Inc

27.220

+0.720+2.72%

Overview Financials Analysis Company

Overview

Financials

Analysis

Company

Intraday

30m

Today

+2.72%

5 Days

+2.95%

1 Month

+7.04%

6 Months

+13.75%

Year to Date

+9.32%

1 Year

+5.38%

View Detailed Chart

TradingKey Stock Score of Pfizer Inc

Currency: USD Updated: 2026-02-06

Key Insights

Pfizer Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 28.93.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Pfizer Inc's Score

Industry at a Glance

Industry Ranking

47 / 159

Overall Ranking

127 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Pfizer Inc Highlights

StrengthsRisks

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 62.58B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 119.41%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 119.41%.

Overvalued

The company’s latest PE is 19.91, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.86B shares, decreasing 2.05% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 110.69K shares of this stock.

Analyst Rating

Based on 29 analysts

Hold

Current Rating

28.930

Target Price

+9.21%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Pfizer Inc News

China Adds Eli Lilly and Pfizer to Its First Private Insurance List — Is This a Buying Opportunity for Biotech Investors?

TradingKey - China officially unveiled its first list of innovative drugs covered by commercial health insurance on December 7, greenlighting 19 high-priced therapies previously excluded from the National Reimbursement Drug List (NRDL).

TradingKeyMon, Dec 8

[Reuters Breakingviews] Obesity kings’ buffet is slimmer than it looks

Obesity kings’ plump future is under siege. Over the past month Roche ROG.S and Pfizer PFE.N have splurged over $10 billion scooping up promising treatments and other rivals are rapidly developing their own medicines. Incumbents $242 billion Novo Nordisk NOVOb.CO and $722 billion Eli Lilly LLY.N may

ReutersThu, Oct 2